Complete remission of pulmonary metastases of Bellini duct carcinoma with cisplatin, gemcitabine and bevacizumab: a case report

Abstract

SummaryBackground:Bellini carcinomas, rare tumors of kidney, are aggressive and have a poor prognosis. For these cancers, there is no standard treatment regimen and chemotherapy for urothelial cancer is usually used.Case Report:In a 44-year-old man with hematuria, a tumor was diagnosed in the right kidney. After radical nephrectomy, pathologic analysis revealed Bellini carcinoma, staged pT3apN0, Fuhrman grade 3. Secondary pulmonary lesions occur one year later. Chemotherapy (gemcitabine, cisplatin and bevacizumab) was started and after 2 cycles of chemotherapy, Thoracic CT scans showed good response to treatment, with almost complete regression of the pulmonary lesions. After the third cycle of chemotherapy, maintenance treatment with bevacizumab continued. Fifteen months after diagnosing pulmonary metastases, hilar adenopathies progressed slightly and cisplatin-gemcitabine was started again leading to a partial response after five courses. Approximately 2 years after the diagnosis of lung metastases, the patient presented a second relapse, so carboplatin-gemcitabine was started, while bevacizumab was continued. 24 months after the diagnosis of lung metastases, the patient was still alive with controlled disease.Conclusions:In view of our findings, a prospective multicenter trial with cisplatin, gemcitabine and bevacizumab in patients with metastatic collecting duct carcinoma is planned.

Collecting (Bellini) duct carcinoma: A clinical study of a rare tumour and review of the literature

“…7 Procopio and colleagues assessed 13 patients with CDC receiving targeted therapies and 3 patients experienced periods of disease stabilization. 19 Miyake and CUAJ • September-October 2015 • Volume 9, Issues 9-10 E592 ciszewski et al collecting (Bellini) duct carcinoma colleagues 20 and Chua and colleagues 21 presented case reports of partial response of metastatic CDC after sunitinib therapy. Ansari and colleagues reported a response, with minimal side effects, to sorafenib in a patient with metastatic CDC.…”

Surgical monotherapy may be a suitable therapeutic strategy for advanced collecting (Bellini) duct carcinoma: A case report and literature review

“…Staehler et al (11) reported two stage T3aN2M0 CDC cases treated with RN plus combined therapy (first line, gemcitabine + cisplatin; second line, sunitinib); both patients succumbed to the disease 8 months after the initial diagnosis. However, Barrascout et al (12) described a patient with T3aN0m0 CDC treated with RN plus combined therapy (gemcitabine, cisplatin and bevacizumab) who survived >35 months following the initial diagnosis.…”

Rechallenge of carboplatin‑gemcitabine based chemotherapy for rapidly progressing metastatic collecting duct carcinoma of the kidney leading to a delayed and durable complete response: A case report

“…Two studies (one phase II single arm trial with 5 patients and one case report) suggested that addition of bevacizumab to platinum-based chemotherapy could improve efficacy of chemotherapy. These preliminary results need to be confirmed (8,9). Bevacizumab is still under evaluation in combination with GC based-chemotherapy in metastatic renal CDC [BEVABEL GETUG-AFU phase 2 Trial (NCT02363751)].…”